Life Sciences

Brian Goldstein, Bob Licht, Charles Lyon
 Eric Marandett, Fred Callori Brenda Jarrell

Private Company Clients

3D Matrix
Adimab
Allertein Therapeutics
Anterios
Axerion Therapeutics
Clarient
Constellation Pharmaceuticals
Excelimmune
Firefly Bioworks
GeNO
Greer Laboratories
Kapa Biosystems
Merz USA
Nimbus
Putney
Satori Pharma
Symbiotix Biotherapies
SynapDx
Synchroneuron
Tarix Pharmaceuticals

Public Company Clients

Agenus
Aveo Oncology
Biogen Idec
Celgene Avilomics Research
CoNCERT Pharmaceuticals
Cubist
Eisai Co.
Foundation Medicine
Genocea Biosciences
Ironwood Pharmaceuticals
Momenta Pharmaceuticals
Oxford Immunotec
PerkinElmer
Pfizer
Progenics
Regeneron Pharmaceuticals
Sanofi Pasteur
Shionogi
Shire
Siemens Healthcare
Takeda
TESARO
Tokai Pharmaceuticals
Trinity Biotech
VBI Vaccines

Research Institution Clients

Brandeis University
Cornell University
Harvard University
Mass General Hospital
Memorial Sloan-Kettering
Mass Institute of Technology
Tufts University
University of Maine
Vanderbilt University

Preeminent Investment Clients

Apple Tree Partners
Atlas Venture Fund
Ascent Ventures
BDC
Broadview Ventures
Canaccord Genuity
Clarus Ventures
Essex Woodlands
Flagship Ventures
Genesys Capital
Investor Growth Capital
Kearney Venture Partners
Lazard Freres & Co.
MPM Capital
Needham & Company
OrbiMed
Pappas Ventures
Polaris Venture
ProQuest Investments
PureTech Ventures
Rho Ventures
Sanderling
SR One
Summit Partners
Third Rock Ventures

Scientific & Strategic Expertise

Team of IP attorneys, patent agents and staff scientists, many with PhDs or other advanced degrees, and also with industry expertise in major areas, including:

 

  • Biologics
  • Biosimilars
  • Biotechnology
  • Cardiology
  • Diagnostics
  • Drug delivery/formulation
  • Genomics
  • Immunology
  • Infectious diseases
  • Medical devices
  • Metabolic disorders
  • Nanotechnology
  • Neuroscience
  • Oncology
  • Personalized medicine
  • Pharmaceuticals
  • Proteomics
  • Systems biology
  • Vaccines
  • Choate named to IAM Patent 1000: The World’s Leading Patent Professionals for IP Prosecution, Transactions, and Litigation. Read more...

  • Dr. Brenda Jarrell and Dr. Charles Lyon were recently named "IP Trailblazers" by The National Law Journal. Read more...

  • Choate received top national rankings in bio/life sciences, patent prosecution, and patent litigation from Managing Intellectual PropertyRead more...

  • legalTV
  • toggle

    Choate recently obtained a preliminary injunction for Momenta Pharmaceuticals in a patent infringement action to preserve exclusivity in sales of the only generic form of enoxaparin, which had more than $1 billion in sales in its first 12 months.  Choate immediately sued and moved for a TRO and Preliminary injunction based on infringement of two patents covering methods used in the process of making the product, after another party announced in September, 2011 that it had obtained FDA approval to market a second generic enoxaparin.   Choate successfully obtained the TRO and then a preliminary injunction after several rounds of briefing and hearings, also surviving a motion to dismiss, thereby successfully keeping the rival product entirely off the market until trial.   

  • toggle

    Choate represented privately held oncology-focused pharmaceutical company Tesaro, Inc. in its acquisition of an oncology supportive care product from OPKO Health, Inc., a publicly traded healthcare company involved in the discovery, development and commercialization of pharmaceutical products.

  • toggle

    Choate counsels multiple companies focused on engineering microbial cells to produce chemical compounds of interest, and the firm has secured for such companies the issued patents to engineered strains.

 

Life Sciences

"the ‘fantastic firm’ has legendary prowess in life sciences and meets the needs of many of the country’s most technically demanding patent holders"   

IAM Patent 1000

Nationally Recognized Experts in Life Sciences 

Represent leading life sciences companies and institutions in all aspects of their business, including IP protection, strategies, collaborations and licenses, technology transfer, financings, M&A transactions and general advice and counsel.

Corporate Experience 

Representation of emerging and public companies.  Expertise in public and private financing representing companies and investors.  Preeminent M&A and cross-border transactional practice. Nationally ranked among the leading firms for Life Sciences, M&A, Private Equity Buyouts and Venture Capital and Emerging Companies by The Legal 500 guide to preeminent law firms in US.

Full Range of IP Services 

Full range of services, including strategic IP counseling; patent prosecution; trademark prosecution; copyright protection; trade secrets and unfair competition counseling; and IP due diligence for investors and acquirers.  Decades of litigation experience representing life sciences companies in IP disputes.  One of first major Boston firms to establish patent group.  Ranked as patent strategy and management team of the year by LMG Life Sciences.  Recognized among the world’s leading patent practitioners for Prosecution and Transactions in the IAM Patent 1000.  Ranked as a top Tier 1, “highly recommended” firm for Intellectual Property in Massachusetts, as well as a top firm nationally for Bio Life Sciences, Patent Prosecution and Patent Contentious, by Managing Intellectual Property.

World-Class Transactional & Licensing Capability 

Among most experienced and knowledgeable technology transaction, strategic collaboration and licensing lawyers in US, representing pharmaceutical and biotechnology companies in all types of transactions, including strategic alliances, collaborations, joint ventures and license arrangements.

National/International Reach 

Represent life sciences companies and institutions across United States and many foreign countries.  Preeminent US – Canada cross-border practice.

 

Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.

AcceptDecline